Results 81 to 90 of about 1,796 (202)

Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123 [PDF]

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic cancer originating from the malignant transformation of plasmacytoid dendritic cell precursors.
De Filippi R, Galati D, Pinto A., Zanotta S   +3 more
core   +1 more source

Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment

Frontiers in Medicine
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematological malignancy with a highly aggressive behavior and median survival of <2 years. Especially, most BPDCN patients present with extensive and non-specific skin lesions,
Xiaoning Wang, Xiaoning Wang, Jiashuo Guo, Jiashuo Guo, Yan Liu, Na Zheng, Shaohan Xu, Shaohan Xu, Lianhui Wu, Ruirui Yuan, Liying Xue, Jie Li   +11 more
doaj   +1 more source

First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

Journal of Hematology & Oncology, 2018
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9–13 months.
Weili Sun, Huaying Liu, Young Kim, Nicole Karras, Anna Pawlowska, Debbie Toomey, Wade Kyono, Paul Gaynon, Joseph Rosenthal, Anthony Stein   +9 more
doaj   +1 more source

Effects of a Low Versus Moderate–High Intense Exercise Program on Innate Immune Recovery, Fitness, and Quality of Life During Pediatric Allo‐HSCT—The ANIMAL Exploratory Randomized Controlled Trial

Pediatric Blood &Cancer, Volume 72, Issue 8, August 2025.
ABSTRACT Objectives Pediatric cancer patients undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT) are severely immunosuppressed leading to a high risk for life‐threatening infections. This trial investigates the effects of exercise during allo‐HSCT on immune cell recovery and patient‐related outcomes (DRKS00019865). Methods Twenty‐
Ronja Beller, Sabrina B. Bennstein, Dirk Reinhardt, Gabriele Gauß, Carolina Chamorra Vina, Helmut Hanenberg, Markus Uhrberg, Miriam Götte   +7 more
wiley   +1 more source

Clinical management of CMML—State of the art

British Journal of Haematology, Volume 207, Issue 2, Page 350-364, August 2025.
Patients with chronic myelomonocytic leukaemia (CMML) typically present with clinical feature including splenomegaly, constitutional symptoms and autoimmune phenomena, as well as with pathological blood counts and biological features in the marrow. These characteristics may influence the assignment to prognostic categories such as the CPSSmol and also ...
K. Nachtkamp, F. Schulz, N. Gattermann, U. Germing   +3 more
wiley   +1 more source

Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm? [PDF]

PLoS ONE, 2013
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy. Plasmacytoid DCs (pDCs), which are defined as lineage marker (Lin)(-)HLA-DR(+)CD56(-)CD123(+)CD11c(-) cells, are considered to be the normal counterpart of BPDCNs ...
Yohei Osaki, Akihiko Yokohama, Akio Saito, Kenichi Tahara, Kunio Yanagisawa, Yoshiyuki Ogawa, Takuma Ishizaki, Takeki Mitsui, Hiromi Koiso, Makiko Takizawa, Hideki Uchiumi, Takayuki Saitoh, Hiroshi Handa, Hirokazu Murakami, Norifumi Tsukamoto, Yoshihisa Nojima   +15 more
doaj   +1 more source

Pathology Quiz Case: Plasmacytoid Dendritic Cell Neoplasm

Allergy & Rhinology, 2014
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that possesses a heterogenous clinical and immunophenotypic presentation. The current case report describes an interesting and unique presentation of BPDCN as a primary
Quinn A. Dunlap B.S., Kristine E. Day M.D., Samuel G. Borak M.D., Bradford A. Woodworth M.D.   +3 more
doaj   +1 more source

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. [PDF]

Blood Neoplasia
Pemmaraju N, Phan LH, Fell G, Luskin MR, Swaminathan M, Pierce S, DiNardo C, Maiti A, Konopleva M, Lane AA.   +9 more
europepmc   +3 more sources

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature. [PDF]

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available.
Betticher, D., Cantoni, N., Hayoz, S., Hitz, F., Medinger, M., Meier-Lienhard, R., Pabst, T., Passweg, J.R., Schmidt, A., Simeon, L., Spertini, O., Suter, C.   +11 more
core   +1 more source

Efficacy and Safety of Combining r‐ATG With PTCy for GvHD Prophylaxis in Haploidentical HSC Transplantation for Malignancies—A Systematic Review

Journal of Cellular and Molecular Medicine, Volume 29, Issue 11, June 2025.
ABSTRACT Allogeneic haematopoietic stem cell transplantation (HSCT) for haematological malignancies can cause acute and chronic graft‐versus‐host disease (GvHD), impacting graft success and mortality. Rabbit anti‐thymocyte globulin (r‐ATG) or post‐transplant cyclophosphamide (PTCy) is effective in reducing GvHD in haploidentical‐HSCT.
Joseph M. John, Uday Kulkarni, Dinesh Pendharkar, Sachin Jadhav   +3 more
wiley   +1 more source